Read by QxMD icon Read

Screening in prostate cancer

Britton Trabert, Ronald C Eldridge, Ruth M Pfeiffer, Meredith S Shiels, Troy J Kemp, Chantal Guillemette, Patricia Hartge, Mark E Sherman, Louise A Brinton, Amanda Black, Anil K Chaturvedi, Allan Hildesheim, Sonja I Berndt, Mahboobeh Safaeian, Ligia Pinto, Nicolas Wentzensen
Inflammation is proposed to increase risk of developing endometrial cancer, but few prospective epidemiologic studies have investigated the relationship between circulating inflammation markers and endometrial cancer risk. In a nested case-control study within the PLCO Screening Trial we measured serum levels of 64 inflammation-related biomarkers in 284 incident endometrial cancer cases and 284 matched controls. Using multivariable logistic regression inflammation markers were evaluated individually and combined into a cross-validated inflammation score...
October 22, 2016: International Journal of Cancer. Journal International du Cancer
Stacy Loeb, Yasin Folkvaljon, Caitlin Curnyn, David Robinson, Ola Bratt, Pär Stattin
Importance: Active surveillance is an important option to reduce prostate cancer overtreatment, but it remains underutilized in many countries. Models from the United States show that greater use of active surveillance is important for prostate cancer screening to be cost-effective. Objectives: To perform an up-to-date, nationwide, population-based study on use of active surveillance for localized prostate cancer in Sweden. Design, Setting, and Participants: Cross-sectional study in the National Prostate Cancer Register (NPCR) of Sweden from 2009 through 2014...
October 20, 2016: JAMA Oncology
Jianguo Zhu, Jukun Song, Zezhen Liu, Jin Han, Heng Luo, Yunlin Liu, Zhenyu Jia, Yuanbo Dong, Wei Zhang, Funeng Jiang, Chinlee Wu, Zaolin Sun, Weide Zhong
Association between allergic conditions and prostate cancer risk has been investigated for many years. However, the results from available evidence for the association are inconsistent. We conducted a meta-analysis to evaluate the relationship between allergic conditions (asthma, atopy, hay fever and "any allergy") and risk of prostate cancer. The PubMed and Embase databases were searched to screen observational studies meeting our meta-analysis criteria. Study selection and data extraction from included studies were independently performed by two authors...
October 21, 2016: Scientific Reports
Changqing Yin, Changliang Luo, Wei Hu, Xu Ding, Chunhui Yuan, Fubing Wang
As part of "liquid biopsy," lots of literature indicated the potential diagnostic value of circulating cell-free DNA (cfDNA) in the management of prostate cancer (PCa). However, the literature on the accuracy of cfDNA detection in PCa has been inconsistent. Hence, we performed this meta-analysis to assess the diagnostic value of cfDNA in PCa. A total of 19 articles were included in this analysis according to the inclusion and exclusion criteria. We then investigated two main subgroups in this meta-analysis, including qualitative analysis of abnormal level of cfDNA and qualitative analysis of single-gene methylation alterations...
2016: Disease Markers
Paulette Cutruzzula, Daniel Edwards, David Cahn, Carmen Tong, Dana Kivlin, Laurence Belkoff
A 69 year-old homeless African American male with prostate cancer diagnosed 2 years prior presents a large mass in the right thigh. Evaluation of the patient revealed a PSA of 9,362 ng/ml. IR biopsy of the leg mass was performed and final pathology indicated metastatic adenocarcinoma of the prostate. While metastatic prostate cancer presents most commonly in bone, lymph nodes, lungs and liver, metastatic disease presenting as a soft tissue mass is extremely rare.(1,2,3) Advent of screening with PSA has led to earlier diagnosis of lower grade disease, yet underserved populations continue to present with aggressive and morbid disease...
October 17, 2016: Urology
Majid Barati, Mohammad Ali Amirzargar, Saeed Bashirian, Vahid Kafami, Amir Abbas Mousali, Babak Moeini
BACKGROUND: Prostate cancer is the fourth most common cancer worldwide and is the second most lethal cancer. OBJECTIVES: The aim of this study was to investigate psychological predictors of prostate cancer screening behaviors among men over 50 years of age in Hamadan. MATERIALS AND METHODS: This cross-sectional study was carried out on 200 men over 50 years of age in Hamadan, west of Iran. Participants were recruited with a cluster sampling method...
August 2016: Iranian Journal of Cancer Prevention
Thais Caldara Mussi, Yves Bohrer Costa, Marcos Takeo Obara, Marcos Roberto Gomes de Queiroz, Rodrigo Gobbo Garcia, José Antonio Domingos Cianciarulo Longo, Gustavo Caserta Lemos, Ronaldo Hueb Baroni
Objective: To describe the imaging findings of prostatic tumors nonadenocarcinoma on multiparametric magnetic resonance imaging. Methods: A total of 200 patients underwented multiparametric magnetic resonance imaging of the prostate for screening for prostate cancer, from August 2013 to September 2014, followed by biopsy with ultrasound/magnetic resonance imaging fusion. Results: We found three pathologic proved cases of prostatic pure leiomyomas (0...
July 2016: Einstein
Andrew Keller, Christian Gericke, Jennifer A Whitty, John Yaxley, Boon Kua, Geoff Coughlin, Troy Gianduzzo
BACKGROUND AND OBJECTIVES: The Göteborg randomised population-based prostate cancer screening trial demonstrated that prostate-specific antigen (PSA)-based screening reduces prostate cancer deaths compared with an age-matched control group. Utilising the prostate cancer detection rates from this study, we investigated the clinical and cost effectiveness of a similar PSA-based screening strategy for an Australian population of men aged 50-69 years. METHODS: A decision model that incorporated Markov processes was developed from a health system perspective...
October 18, 2016: Applied Health Economics and Health Policy
Michael T Schweizer, Heather H Cheng, Maria S Tretiakova, Funda Vakar-Lopez, Nola Klemfuss, Eric Q Konnick, Elahe A Mostaghel, Peter S Nelson, Evan Y Yu, R Bruce Montgomery, Lawrence D True, Colin C Pritchard
Precision oncology entails making treatment decisions based on a tumor's molecular characteristics. For prostate cancer, identifying clinically relevant molecular subgroups is challenging, as molecular profiling is not routine outside of academic centers. Since histologic variants of other cancers correlates with specific genomic alterations, we sought to determine if ductal adenocarcinoma of the prostate (dPC) - a rare and aggressive histopathologic variant - was associated with any recurrent actionable mutations...
October 15, 2016: Oncotarget
Kalle J Kaapu, Teemu J Murtola, Kirsi Talala, Kimmo Taari, Teuvo Lj Tammela, Anssi Auvinen
BACKGROUND: Protective effects have been suggested for digoxin against prostate cancer risk. However, few studies have evaluated the possible effects on prostate cancer-specific survival. We studied the association between use of digoxin or beta-blocker sotalol and prostate cancer-specific survival as compared with users of other antiarrhythmic drugs in a retrospective cohort study. METHODS: Our study population consisted of 6537 prostate cancer cases from the Finnish Randomized Study of Screening for Prostate Cancer diagnosed during 1996-2009 (485 digoxin users)...
October 18, 2016: British Journal of Cancer
Scott P Kelly, Barry I Graubard, Gabriella Andreotti, Naji Younes, Sean D Cleary, Michael B Cook
BACKGROUND: Evidence suggests that obesity in adulthood is associated with increased risk of "clinically significant" prostate cancer. However, studies of body mass index (BMI) across the adult life course and prostate cancer risks remain limited. METHODS: In a prospective cohort of 69 873 men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, we examined associations of prediagnostic BMI across the adult life course with risk of incident prostate cancer and fatal prostate cancer (prostate cancer-specific mortality)...
March 2017: Journal of the National Cancer Institute
Simon B Zeichner, Christine Stanislaw, Jane L Meisel
In recent years, we have learned a great deal about pathogenic mutations that increase the risk of breast and ovarian cancer, particularly mutations in the BRCA1 and BRCA2 genes. Here we review current guidelines on breast and ovarian cancer screening, prophylactic surgery, and other risk-reduction strategies in patients with these mutations, and we detail the data that drive these recommendations. We also discuss guidelines on screening and management for other cancers associated with BRCA1 and BRCA2, such as male breast cancer, pancreatic cancer, and prostate cancer...
October 15, 2016: Oncology (Williston Park, NY)
J Cohen, C Andre, P Mozer
Prostate cancer is the first cancer and the second cause of cancer death in men in France. It is now a major public health issue, particularly given the increase of life expectancy. If screening is based on blood PSA and clinical examination (DRE), diagnosis requires the histological analysis of prostate samples. In current clinical routine, these biopsies are performed by endorectal through ultrasound guidance. In most cases, the cancer is not visible in the ultrasound image and the latter is used to make a dozen samples (or core), distributed as best as possible in the prostate...
October 14, 2016: Progrès en Urologie
Sarah A Altınoğlu, Ming Wang, Kathleen Q Li, Yuyang Li, Qiaobing Xu
The phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor, mutated or inactive in a large percentage of human cancers. Restoring PTEN activity in cancer cells through gene therapy has shown to inhibit cell growth and induce apoptosis, particularly in cells with a PTEN deficiency. Gene therapy, however, comes with some inherent risks such as triggering an immune response and permanent off target effects. Nanoparticle assisted protein delivery could mitigate these liabilities while maintaining therapeutic integrity...
October 17, 2016: Biomaterials Science
Michael S Leapman, Peter R Carroll
INTRODUCTION: Selective treatment approaches for prostate cancer (PCa) are warranted given the highly varied nature of the disease and the consequences associated with definitive therapy. MATERIALS AND METHODS: We present a stepwise overview of strategies to not treat PCa, ranging from improved early detection practices that seek to improve the yield at initial diagnosis, as well as refinements to risk prediction and the performance of active surveillance. RESULTS: Adherence to screening guidelines is non-uniform...
October 13, 2016: Urologic Oncology
Akhil Muthigi, Abhinav Sidana, Arvin K George, Michael Kongnyuy, Mahir Maruf, Subin Valayil, Bradford J Wood, Peter A Pinto
INTRODUCTION AND OBJECTIVE: Multiparametric magnetic resonance imaging (MRI) and magnetic resonance (MR) -targeted biopsy have a growing role in the screening and evaluation of prostate cancer. We aim to evaluate the current knowledge, attitude, and practice patterns of urologists regarding this new technique. METHODS: An anonymous online questionnaire was designed to collect information on urologists' beliefs and use of prostate multiparametric MRI and MR-targeted biopsy...
October 12, 2016: Urologic Oncology
Xiaozhou Fan, Alexander V Alekseyenko, Jing Wu, Brandilyn A Peters, Eric J Jacobs, Susan M Gapstur, Mark P Purdue, Christian C Abnet, Rachael Stolzenberg-Solomon, George Miller, Jacques Ravel, Richard B Hayes, Jiyoung Ahn
OBJECTIVE: A history of periodontal disease and the presence of circulating antibodies to selected oral pathogens have been associated with increased risk of pancreatic cancer; however, direct relationships of oral microbes with pancreatic cancer have not been evaluated in prospective studies. We examine the relationship of oral microbiota with subsequent risk of pancreatic cancer in a large nested case-control study. DESIGN: We selected 361 incident adenocarcinoma of pancreas and 371 matched controls from two prospective cohort studies, the American Cancer Society Cancer Prevention Study II and the National Cancer Institute Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial...
October 14, 2016: Gut
Roman Gulati, Heather H Cheng, Paul H Lange, Peter S Nelson, Ruth Etzioni
BACKGROUND: Guidelines for prostate-specific antigen (PSA) screening in subgroups with increased risk of prostate cancer (PCa) diagnosis due to race or genotype are underdeveloped. Our goal was to investigate types of increased PCa risk and implications for targeted screening. METHODS: Computer simulation of subgroups with average and hypothetical increased risk(s) of onset of latent disease, progression, and/or cancer-specific death. For each subgroup, we predicted lifetime probabilities of overdiagnosis and life saved under more and less intensive PSA screening strategies...
October 14, 2016: Cancer Epidemiology, Biomarkers & Prevention
Kosei Nakajima, Lance K Heilbrun, Daryn Smith, Victor Hogan, Avraham Raz, Elisabeth Heath
The U.S. Preventive Services Task Force (USPSTF) has recommended against PSA-based screening for prostate cancer due to potential possibilities of false-results. Since no alternative test is available to replace it, we have initiated a trial with the purpose of establishing whether Galectin-3 (Gal-3) serum level and/or the patients' immune response to PSA and Gal-3 antigens could complement the PSA test as diagnostic tools for prostate cancer patients. A blind, prospective, single institution, pilot study was conducted...
October 12, 2016: Oncotarget
M H Jazayeri, H Amani, A A Pourfatollah, A Avan, G A Ferns, H Pazoki-Toroudi
Prostate-specific antigen (PSA) is used to screen for prostate disease, although it has several limitations in its application as an organ-specific or cancer-specific marker. Furthermore, a highly specific/sensitive and/or label-free identification of PSA still remains a challenge in the diagnosis of prostate anomalies. We aimed to develop a gold nanoparticle (GNP)-conjugated anti-PSA antibody-based localized surface plasmon resonance (LSPR) as a novel approach to detect prostatic disease. A total of 25 nm colloidal gold particles were prepared followed by conjugation with anti-PSA pAb (GNPs-PSA pAb)...
October 14, 2016: Cancer Gene Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"